BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Sunday, November 24, 2024
See today's BioWorld
Home
» Tetraphase Lands $67M BARDA Contract for Antibiotic TP-434
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Tetraphase Lands $67M BARDA Contract for Antibiotic TP-434
Feb. 17, 2012
By
Trista Morrison
No Comments
Less than six months after winning a $36 million National Institutes of Health (NIH) contract for respiratory antibiotic TP-271, Tetraphase Pharmaceuticals Inc. landed a $67 million BARDA contract for broad-spectrum antibiotic TP-434.
BioWorld